<DOC>
	<DOC>NCT02831387</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of treatment with 0.017% P-321 on Dry Eye Symptoms.</brief_summary>
	<brief_title>Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease</brief_title>
	<detailed_description>This is a multi-center, randomized, double-masked, placebo-controlled, parallel group Phase 2b trial designed to evaluate symptoms and signs in subjects with mild to moderate dry eye disease. Eligible patients, will be treated with placebo during 2-week placebo run-in period. Subjects will then be randomly assigned in a double-masked, 1:1 ratio to either 0.017% P-321 Ophthalmic Solution or placebo TID for 28 days. This study is designed to evaluate the changes in symptoms. Safety will be assessed throughout the study by adverse events.</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1. Provide written informed consent 2. Male or female subjects aged 18 to 80 years, inclusive 3. Have a history of dry eye disease (DED) in both eyes 4. Be on stable regimens of other needed medications 5. Have a BCVA of +0.7 or better as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) 6. Have reported symptoms 7. Have a Schirmer score without anesthesia of &gt;1 and &lt;10 mm at 5 minutes in both eyes and have staining of conjunctival and corneal areas of the eye. 8. Have normal lid anatomy 1. Have undergone refractive eye surgery 2. Have undergone previous eyelid surgery in either eye 3. Have lid irregularities or deformities 4. Have a history of glaucoma, a history of an elevated lOP within the past year, or an lOP in either eye &gt; 25 mmHg at the Screening Visit (Visit 1) 5. Have any clinically significant, uncontrolled, or unstable medical or surgical conditions that could affect his or her ability to participate 6. Have permanent punctal plugs, punctal occlusion, or history of nasolacrimal duct obstruction. Removable punctal plugs are allowed if they have been used regularly for at least 60 days prior to the screening visit. However, if a plug comes out during the study it must be promptly replaced. 7. Have clinical findings of severe Meibomian Gland Dysfunction (MGD) 8. Are pregnant or breast feeding 9. Use of any investigational product or device within 28 days prior to the Screening Visit or during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>